Jul. 2 at 1:07 PM
$VRDN Optho KOLs/ commenting on Veligrotug approval: "...I find that the veligrotug data, which demonstrate significant improvements for proptosis and diplopia, a rapid onset of benefit after just one infusion, and a shorter course of treatment, will resonate with both patients and treating physicians. What also distinguishes veligrotug is its demonstrated efficacy across both active and chronic TED, addressing the full spectrum of moderate-to-severe disease. For clinicians, veligrotug broadens the conversation considerably as we've historically had limited options for patients in the chronic phase who are still experiencing significant disease burden."
